NCT06548490View on ClinicalTrials.gov

GLP-1R Agonist Treatment for Opioid Use Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 13, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Opioid Use DisorderOpioid Abuse and AddictionNarcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental DisorderOpioid
Interventions
DRUG

Semaglutide Pen Injector

Semaglutide will be provided using an injection pen

DRUG

Placebo

Placebo will be a dry needle stick; no substances will be injected

Trial Locations (3)

10016

RECRUITING

NYU Langone Health, New York

17110

RECRUITING

Pennsylvania Psychiatric Institute, Harrisburg

21223

RECRUITING

University of Maryland Baltimore, Baltimore

All Listed Sponsors
collaborator

New York University

OTHER

collaborator

University of Maryland

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Milton S. Hershey Medical Center

OTHER